Loading
A phase 2 trial of nimotuzumab and gemcitabine + nab-paclitaxel in pancreatic cancer, run by Zhejiang University, now recruiting.
HRS-4642 With Nimotuzumab and Chemotherapy for First-line Treatment of Advanced Pancreatic Cancer Patients is a phase 2, randomised interventional study registered as NCT06770452 by Zhejiang University, with a registry enrolment figure of 133 participants, started 2025-03-25 and due to reach its primary completion in 2027-02-01. Interventions recorded: HRS-4642; Nimotuzumab; gemcitabine + nab-paclitaxel. Conditions listed: Metastatic Pancreatic Carcinoma. Primary outcome: Objective reponse rate (ORR). Pancreatic eligibility wording from the registry: "Metastatic pancreatic cancer (from pancreatic ductal epithelium) for Arm A; Locally advanced pancreatic cancer (from pancreatic ductal epithelium) for Arm B; 3". Sites: China. No results are recorded here; the registry entry is the source.
Shares Gemcitabine + nab-paclitaxel, Locally advanced unresectable pancreatic ductal adenocarcinoma, Pancreatic cancer trials open today (registry snapshot and UK sites), Metastatic pancreatic ductal adenocarcinoma and the tag pancreatic-deep-dive.
Shares Gemcitabine + nab-paclitaxel, Locally advanced unresectable pancreatic ductal adenocarcinoma, Pancreatic cancer trials open today (registry snapshot and UK sites), Metastatic pancreatic ductal adenocarcinoma and the tag pancreatic-deep-dive.
Shares Nimotuzumab, Gemcitabine + nab-paclitaxel, Locally advanced unresectable pancreatic ductal adenocarcinoma, Pancreatic cancer trials open today (registry snapshot and UK sites) and the tag pancreatic-deep-dive.
Shares Gemcitabine + nab-paclitaxel, Locally advanced unresectable pancreatic ductal adenocarcinoma, Pancreatic cancer trials open today (registry snapshot and UK sites), Metastatic pancreatic ductal adenocarcinoma and the tag pancreatic-deep-dive.
Shares Nimotuzumab, Locally advanced unresectable pancreatic ductal adenocarcinoma, Pancreatic cancer trials open today (registry snapshot and UK sites), Metastatic pancreatic ductal adenocarcinoma and the tag pancreatic-deep-dive.
Shares Gemcitabine + nab-paclitaxel, Pancreatic cancer trials open today (registry snapshot and UK sites), Metastatic pancreatic ductal adenocarcinoma, Cytotoxic chemotherapy and the tag pancreatic-deep-dive.
Shares Nimotuzumab, Gemcitabine + nab-paclitaxel, Pancreatic cancer trials open today (registry snapshot and UK sites), Cytotoxic chemotherapy and the tag pancreatic-deep-dive.
Shares Gemcitabine + nab-paclitaxel, Locally advanced unresectable pancreatic ductal adenocarcinoma, Pancreatic cancer trials open today (registry snapshot and UK sites), Metastatic pancreatic ductal adenocarcinoma and the tag pancreatic-deep-dive.